Polyps

Polyps: A Comprehensive Natural-Health and Nutritional Reference

1. Definition and Overview

The word "polyp" arises from the ancient Greek word polypus, meaning "many feet." In medicine, a polyp is an abnormal growth of tissue protruding from the mucosal membrane into the lumen of a hollow vessel, and these growths can arise anywhere in the gastrointestinal, genitourinary, or respiratory tracts. Polyps can arise from any mucus membrane in the body, and they are usually benign. Most are not cancerous, but a polyp contains abnormal cells or cells that may become abnormal.

Within the gastrointestinal tract, polyps can be found in the esophagus, the stomach, the duodenum, the colon, and the rectum, with colorectal polyps accounting for the vast majority of polyps found in the GI tract. While most polyps are largely asymptomatic, and despite the majority of polyps being benign, certain types can become malignant and develop into cancer if left unaddressed.

Polyps often develop insidiously, without specific clinical symptoms, and their pathogenesis remains unclear. Polyp development is closely associated with endocrine disorders, genetics, age, medications, and lifestyle habits.

2. Types of Polyps and Body Systems Involved

2.1 Colorectal Polyps

Colorectal polyps are classified histologically as neoplastic or non-neoplastic. The majority of polyps are small, non-neoplastic lesions that are found during screening or when procedures are performed for other diagnostic reasons, such as a gastrointestinal bleed.

Polyps can be classified by their malignant potential. Hyperplastic polyps are the most common type of polyp in the colon, accounting for 90% of all polyps detected. Hyperplastic, hamartomatous/juvenile, and inflammatory polyps are considered to have no malignant potential. Although only 5% of adenomas evolve to cancer, it is accepted that the majority of carcinomas evolve from adenomatous polyps. Adenomatous polyps should therefore be considered as precursors to carcinomas and should be removed whenever possible. Serrated-adenoma polyps have recently been identified and display features of both non-malignant and moderate-malignant potential.

Adenomatous polyps can be further categorized into subtypes: tubular adenoma (approximately 4% malignant potential), tubulovillous adenoma (approximately 16% malignant potential), and villous adenoma (approximately 21% malignant potential). All adenomas have variable degrees of dysplasia ranging from low-grade to high-grade. The malignant potential of adenomas correlates with polyp type, size, and degree of dysplasia. Higher grades of dysplasia, increasing percentage of villous tissue within the polyp, and polyps greater than 1 cm in diameter are associated with increased risk of malignancy.

Adenomatous polyps or adenomas account for approximately 70% of colon polyps and have the potential to progress to colorectal cancer (CRC) over time if not screened and removed by colonoscopy or sigmoidoscopy.

2.2 Morphological Classification

Polyps can also be classified by their visual appearance. Sessile polyps are broad-based without a connecting stalk; they arise directly from the mucosal layer and account for approximately 50% of all polyps. Pedunculated polyps have a stalk, and semi-pedunculated types represent an intermediate morphology.

2.3 Serrated Polyps

Studies over the past decade have shown that colorectal serrated polyps also have the potential to progress to CRC, with 10–30% of CRC developing through serrated polyps. Serrated polyps are most commonly classified as hyperplastic polyps (HP), sessile serrated adenomas/polyps (SSA/P), and traditional serrated adenomas.

2.4 Gastric Polyps

Among individuals undergoing gastroscopy, the incidence of gastric polyps is 6.35%, with 77% being fundic gland polyps, 17% hyperplastic polyps, and malignant tumors being relatively uncommon.

2.5 Nasal Polyps

Metabolic abnormalities resulting from gut microbial dysbiosis have been identified as a risk factor for chronic sinusitis. Chronic sinusitis frequently coexists with nasal polyps, characterized by eosinophil recruitment due to abnormal activation of immune cells such as CD4+ T cells and Th2 cells. This localized immune remodeling is considered an important contributor to nasal polyp development. Nasal secretions, nasal blockage, sneezing, impaired sense of smell, male sex, increasing age, and asthma are symptoms and risk factors associated with nasal polyps. Nasal polyps are frequently found to run in families, suggesting a hereditary or shared environmental factor; in one study, more than half of 224 nasal polyp patients had a positive family history.

2.6 Endometrial and Gynecological Polyps

Endometrial polyps are benign growths of the endometrium, containing both glandular and stromal elements, including blood vessels. Polyps may be sessile, with a thick and plaque-like base, or pedunculated, sometimes extending into or through the cervix. Postmenopausal women are at higher risk of having malignant endometrial polyps compared to premenopausal women.

3. Contributing and Associated Factors

3.1 Modifiable Lifestyle Factors

A large 2025 systematic review and meta-analysis (Lei et al., Frontiers in Public Health) searching PubMed, Embase, Cochrane Library, and SinoMed (through July 2024) identified several modifiable factors independently associated with colorectal polyp risk across subtypes. Alcohol (OR = 1.63, 95% CI: 1.48–1.78), high-fat diet (OR = 1.45, 95% CI: 1.33–1.57), and smoking (OR = 1.79, 95% CI: 1.69–1.90) significantly increased polyp risk across subtypes. Smoking showed subtype- and region-specific effects, with the highest risk for sessile serrated lesions (SSLs; OR = 3.06, 95% CI: 2.41–3.90).

Type 2 diabetes had the strongest metabolic association (OR = 2.17, 95% CI: 1.82–2.60), followed by hyperlipidemia (OR = 1.50, 95% CI: 1.32–1.70) and hypertension (OR = 1.33).

A colonoscopy-based case-control study of 3,764 polyp-free controls and 2,543 polyp patients found that six factors — cigarette smoking, BMI, NSAID use, and dietary intakes of red meat, fiber, and calcium — were significantly and independently associated with colorectal polyp risk.

3.2 Obesity and Body Mass Index

Odds ratios for colorectal neoplasms (CRN) for incremental body mass index (BMI ≥25) were 2.12 (95% CI: 1.00–4.50) in one colonoscopy-based study. Obesity, in particular, promotes chronic inflammation and insulin resistance while reshaping the gut microbiota in ways that may favor neoplastic progression.

3.3 Red Meat and Processed Meat

A systematic review and meta-analysis of 27 studies involving 208,117 participants and 19,150 colorectal adenoma cases (PMC, 2018) found that the relative risks of the highest versus lowest intakes for colorectal adenoma (CRA) incidence were 1.23 (95% CI: 1.15–1.31) for red meat and 1.15 (95% CI: 1.07–1.24) for processed meat. A 2023 meta-analysis of dietary factors and serrated polyps specifically found that red meat intake increased the risk of serrated polyps by 30% for the highest versus lowest intakes (OR = 1.30, 95% CI: 1.13–1.51).

3.4 Dietary Fiber

Fiber intake (OR = 0.90, 95% CI: 0.82–0.99) was identified as a protective factor against serrated polyps in a 2023 meta-analysis of 28 studies. A dose-response relationship has been established, with a relative risk for developing CRC of 0.90 for an increase of 10 g/day of dietary fiber. A pooled study of fiber and CRC reported inconsistent findings, in which about half of the studies showed a protective effect of fiber while others did not, and these discrepancies could relate to the influence of the gut microbiome.

3.5 Insulin Resistance and Metabolic Syndrome

Physical activity reduces obesity (fat mass), which has a beneficial effect on CRC through a reduction in insulin resistance and inflammation, both of which have been associated with CRC development. Adherence to prudent or fiber-rich dietary patterns (e.g., DASH or alternative Mediterranean diets) was associated with a 30–45% reduction in adenoma risk.

3.6 Physical Inactivity

A meta-analysis by the World Cancer Research Fund estimated that physical activity was associated with a statistically significant 15% reduction in colon polyp risk. A prospective cohort study of 13,057 female nurses found that after controlling for age, prior endoscopy, parental history, smoking, aspirin, and intakes of animal fat, dietary fiber, folate, methionine, and alcohol, physical activity was associated inversely with risk of large (≥1 cm) adenomas in the distal colon (relative risk = 0.57, 95% CI: 0.30–1.08).

3.7 Gut Microbiome

More than a decade after removal of an adenoma from the colon, alterations to the gut microbiome and metabolites remain and may drive heightened risk of colorectal cancer, according to a study by researchers at Harvard T.H. Chan School of Public Health. The study found that diet and physical activity were more closely tied to the abundance of CRC-associated gut microbes in people with a history of adenoma than in adenoma-free individuals. Among participants with a history of adenoma, those with less healthy diets and lower physical activity carried more of the microbes that are typically elevated in both adenoma and CRC patients.

Immune imbalance due to gut microbiota dysbiosis is considered a potential risk factor for polyp formation.

3.8 Genetics and Age

The prevalence of colonic polyps is high and increases with age. Smoking, obesity, low physical activity, sex (increased risk for males), and ethnicity (predominantly in the Non-Hispanic Black population) all contribute to the development of CRC. Inherited conditions such as familial adenomatous polyposis (FAP) are characterized by unregulated development of innumerable pre-cancerous adenomatous growths throughout the colon with eventual development of colorectal cancer at a young age.

4. Nutrients, Herbs, and Natural Ingredients

4.1 Calcium

Scientific Evidence

Calcium has been among the most studied nutrients in relation to colorectal adenoma recurrence. The Vitamin D/Calcium Polyp Prevention Study published in 2015 in the New England Journal of Medicine randomly assigned 2,259 participants to receive daily vitamin D3 (1,000 IU), calcium as carbonate (1,200 mg), both, or neither, in a multicenter, double-blind, placebo-controlled trial at 11 academic medical centers. Overall, 43% of participants had one or more adenomas diagnosed during follow-up.

An earlier randomized clinical trial in 803 subjects found that calcium supplementation and vitamin D status appear to act largely together, not separately, to reduce the risk of colorectal adenoma recurrence. The 2020 systematic review and meta-analysis by Huang et al. in Clinical Nutrition also found additively protective effects of vitamin D and calcium against colorectal adenoma incidence, malignant transformation, and progression.

A review of the evidence concluded that higher intake of calcium alone or when combined with vitamin D was found to be protective against adenoma recurrence, though data from case-control studies are inconsistent but cohort studies and meta-analyses provide evidence on the benefits of circulating, diet-derived, and supplemented vitamin D and calcium.

Notably, a randomized clinical trial (Crockett et al., Gut, 2019) found a complex picture in which calcium and vitamin D supplementation was also associated with increased risk of serrated polyps, illustrating that the relationship between these nutrients and different polyp subtypes is not uniform and requires consideration by polyp type.

For serrated polyps specifically, a 2023 meta-analysis found that higher intakes of vitamin D (OR = 0.95, 95% CI: 0.90–1.02) and calcium (OR = 0.97, 95% CI: 0.91–1.03) were not significantly associated with serrated polyp risk overall.

Evidence strength: Moderate-to-strong for adenomatous polyps from multiple RCTs and meta-analyses; complex and subtype-dependent, with some evidence of differential effects on serrated vs. adenomatous lesions.

4.2 Vitamin D

Scientific Evidence

In the major NEJM trial, participants randomly assigned to receive vitamin D had a mean net increase in serum 25-hydroxyvitamin D levels of 7.83 ng per milliliter relative to participants given placebo. The protective signals for adenomas observed with combined calcium and vitamin D supplementation in multiple trials are discussed above. For serrated polyp subtypes, higher vitamin D intake was associated with a decreased risk of serrated polyps including SSA/P (OR = 0.93, 95% CI: 0.88–0.98).

One review noted that, on the basis of current evidence, one could suggest intake of vitamin D at a dose of 1,000 IU per day, which is regarded as safe, and attaining calcium intakes of 700–800 mg per day, as a reasonable dietary target, though the benefit is strongest in certain population subgroups.

Evidence strength: Moderate for adenomatous polyp prevention, particularly in combined calcium/vitamin D studies; evidence is still accumulating for serrated subtypes.

4.3 Dietary Fiber

Traditional Use

High-fiber diets derived from whole grains, legumes, vegetables, and fruits have been a cornerstone of traditional dietary wisdom in many cultures, valued broadly for digestive health.

Scientific Evidence

The Polyp Prevention Trial (PPT) was a multicenter randomized clinical trial designed to determine the effects of a high-fiber, high-fruit and vegetable, low-fat diet on the recurrence of adenomatous polyps in the large bowel. Adenoma recurrence was ascertained by complete colonoscopy at baseline and after 1 and 4 years. Recurrence was found in 754 of the 1,905 trial participants. The trial did not find that the dietary intervention alone significantly reduced adenoma recurrence, a finding that highlights the complexity of translating dietary fiber associations into clinical interventions.

Mechanistically, diets high in n-3 fatty acids, dietary fiber, folate, vitamin D, calcium, and polyphenols may protect against colorectal cancer and colorectal adenoma formation.

Evidence strength: Observational and meta-analytic evidence consistently shows a protective association; the single large RCT (PPT) did not find a statistically significant effect of a composite dietary intervention on adenoma recurrence.

4.4 Curcumin (Curcuma longa)

Traditional Use

Curcumin is the principal bioactive polyphenol in turmeric (Curcuma longa), a rhizome used for millennia in Ayurvedic and Traditional Chinese Medicine as an anti-inflammatory, digestive, and wound-healing remedy. In Ayurvedic tradition it was used as a paste, powder, and decoction for a wide range of inflammatory and gastrointestinal complaints.

Scientific Evidence

Curcumin is preferentially distributed into the colonic mucosa compared with other tissues, leading many initial clinical studies to focus on identifying whether this compound may play a role in colorectal cancer models.

A small pilot study (Cruz-Correa et al., Clinical Gastroenterology and Hepatology, 2006) examined five FAP patients with prior colectomy who received curcumin 480 mg and quercetin 20 mg orally three times a day. All five patients had a decreased polyp number and size from baseline after a mean of 6 months of treatment. The mean percent decrease in the number and size of polyps from baseline was 60.4% (P < .05) and 50.9% (P < .05), respectively. The authors concluded that the combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with FAP without appreciable toxicity, but randomized controlled trials are needed to validate these findings.

A phase IIA clinical trial on aberrant crypt foci (ACF) found that 41 subjects with 8 or more ACF were recruited and completed the trial. Although curcumin did not affect prostaglandin E2 or 5-HETE levels, a remarkable reduction of 40% in the number of ACF was observed with a dose of 4 g.

However, a later double-blind placebo-controlled trial in FAP patients given curcumin (3 g/d) for 12 months found that treatment with curcumin for 12 months was well tolerated, but no significant change either in the number or size of polyps was observed following curcumin treatment. This contrasted with the earlier pilot study, a discrepancy attributed in part to formulation differences: in their earlier pilot study, the same investigators found colonic polyps to regress in patients treated with curcumin that contained piperine, a compound that enhances the absorption of curcumin.

A 2024 systematic review of 12 low-bias clinical studies found that curcumin demonstrated promise in various trials, mainly decreasing inflammatory cytokines, though results varied, and it did not lower intestinal adenomas or improve outcomes after chemotherapy.

A presurgical proof-of-principle trial combining curcumin and anthocyanin supplementation in colorectal adenomatous polyp patients reported that the combination resulted in a significant borderline reduction of NF-κB expression in adenoma tissue (geometric mean ratio: 0.72; 95% CI: 0.51–1.00) and a trend toward reduction of Ki-67.

The majority of preclinical and clinical studies thus far have found a poor oral bioavailability of curcumin, which remains the primary obstacle to consistent clinical efficacy.

Evidence strength: Preliminary and mixed. Small pilot studies in FAP patients show signal; larger RCTs have not confirmed a significant reduction in adenoma number or size. Bioavailability remains a fundamental challenge.

4.5 Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs)

Traditional Use

Consumption of fish and marine oils has been a traditional dietary practice across coastal and Arctic populations (e.g., Inuit, Scandinavian, Japanese), historically associated with favorable cardiovascular and inflammatory health profiles.

Scientific Evidence

The naturally-occurring omega-3 PUFA eicosapentaenoic acid (EPA) reduces colorectal adenoma (polyp) number and size in patients with familial adenomatous polyposis. The principal omega-3 PUFAs are EPA (C20:5) and DHA (C22:6), which are found predominantly in oily, cold-water fish such as mackerel, having entered the food chain following synthesis by plankton.

A case-control study of the Tennessee Colorectal Polyp Study involving 3,166 polyp-free control subjects and 2,144 subjects with either adenomatous or hyperplastic polyp cases identified by colonoscopy found that regular consumption of omega-3 fatty acids was associated with prevention of colon polyp formation. A 33% reduced risk of colorectal adenomas was observed in women, but not in men.

However, the JAMA Oncology ancillary study of a major randomized clinical trial found that in patients with sporadic colorectal neoplasia, EPA did not affect reductions in the proportion of patients with at least one colorectal adenoma when compared to aspirin or placebo.

A recent PubMed review noted that clinical data suggest that omega-3 fatty acids have differential anti-CRC activity depending on several host factors, including pretreatment blood omega-3 level, ethnicity, and systemic inflammatory response, as well as tumor characteristics including location in the colorectum, histological phenotype, and molecular features.

A meta-analysis of 14 prospective studies failed to show conclusive evidence of the protective effect of either short-chain or long-chain omega-3 PUFAs on colorectal cancer risk. Furthermore, although observational studies support a protective effect of EPA, the first randomized trial of EPA on colorectal adenoma chemoprevention found a null effect on risk reduction. These data suggest that the effect of omega-3 PUFAs on colon adenoma and cancer risk merits further investigation.

Evidence strength: Preliminary and inconsistent. Observational studies and some FAP studies show promise; RCT data in sporadic adenoma have been null or inconclusive. Subgroup effects by sex and molecular phenotype remain under investigation.

4.6 Quercetin

Traditional Use

Quercetin is a flavonoid found abundantly in onions, apples, capers, and many other plant foods. It has a long traditional history of use in European herbal medicine as an anti-inflammatory agent, and has been part of traditional diets across many agricultural cultures.

Scientific Evidence

As detailed above, the pilot FAP trial (Cruz-Correa et al., 2006) used a combination of curcumin and quercetin. Regression of intestinal adenomas in five FAP patients was observed following treatment with curcumin and quercetin. However, this was a very small, uncontrolled study. There is promising evidence for the in vitro and in vivo anticancer activity of quercetin, specifically in colorectal cancer models. There is a clear association between quercetin and resveratrol in interfering with mechanistic pathways involved in CRC, such as Wnt, PI3K/AKT, caspase-3, MAPK, and NF-κB. The major bottleneck in the progression of the use of resveratrol and quercetin as anticancer therapeutics is their reduced bioavailability in vivo because of their rapid metabolism in humans.

Evidence strength: Preclinical evidence is strong; only a single very small uncontrolled human study in FAP exists. Bioavailability limitations constrain translation to clinical use.

4.7 Green Tea and Epigallocatechin Gallate (EGCG)

Traditional Use

Green tea (Camellia sinensis) has been consumed for over 2,000 years in East Asia, particularly in China, Japan, and Korea, and is described in classical texts of Traditional Chinese Medicine as a remedy for digestive complaints, fatigue, and detoxification. EGCG is its primary bioactive catechin.

Scientific Evidence

A systematic review and meta-analysis on tea and colorectal adenomas, searching PubMed, Cochrane Library, Embase, and other databases through April 2023, investigated the association between tea or tea extract consumption and adenoma risk. Neither epigallocatechin gallate (EGCG) nor artepillin C reduced the incidence of adenomas in the low-bias clinical trials assessed. The meta-analysis found no statistically significant modifying effect by study design, type of tea intake, or grade of adenoma.

Several chemopreventive drugs have been suggested to reduce colorectal cancer including aspirin, NSAIDs, antioxidants, and statins. However, no agents have been recommended for the prevention of colorectal cancer in the general population. Therefore, further research is still necessary to find new chemopreventive agents, including green tea and other phytochemicals.

Evidence strength: Preliminary. Preclinical evidence suggests mechanistic plausibility; clinical trial and meta-analytic evidence in adenoma prevention has so far been negative or neutral.

4.8 Folate (Vitamin B9)

Scientific Evidence

Higher folate intake (OR = 0.82, 95% CI: 0.60–1.13) was not significantly associated with serrated polyp risk overall in the 2023 meta-analysis. However, at the subtype level, higher folate intake was associated with a decreased risk of hyperplastic polyps (OR = 0.59, 95% CI: 0.44–0.79). The dietary management literature notes that there is convincing evidence that intake of garlic, vitamin B6, and magnesium, active living, maintaining a healthy weight and waist, and avoiding or reducing red meat, alcohol, and smoking may significantly protect against developing colorectal cancer.

Dietary composition is a widely accepted risk factor for the development of CRC. Consumption of red or processed meat, a high-fat diet, or alcohol are some of the most clearly established dietary risk factors.

Evidence strength: Modest and subtype-dependent; protective association with hyperplastic polyps is more consistent than with adenomatous subtypes.

4.9 Resveratrol

Traditional Use

Resveratrol is a stilbene polyphenol found in grapes, wine, peanuts, and some berries. Its use is not associated with a specific traditional medicinal tradition but is a component of the broad Mediterranean dietary pattern, long associated in epidemiological research with favorable outcomes for gastrointestinal health.

Scientific Evidence

There is promising evidence for the in vitro and in vivo anticancer activity of resveratrol, specifically in the treatment of colorectal cancer. Epidemiological and pre-clinical data suggest that various natural phytochemicals and dietary compounds possess chemopreventive properties, and in vitro and animal studies support that these compounds may modulate signaling pathways involved in cell proliferation and apoptosis. Despite promising results from experimental studies, only a limited number of these compounds have been tested in clinical trials, with variable results.

Evidence strength: Primarily preclinical (in vitro and animal models). Direct clinical evidence for polyp prevention in humans is lacking. Bioavailability remains a significant research challenge.

4.10 Dietary Antioxidants and Patterns

A 2025 Mendelian randomization study using genome-wide association data from the UK Biobank and FinnGen consortium investigated causal relationships between genetically predicted dietary factors, including diet-derived antioxidant intake, and four types of polyps: nasal polyps, female genital tract polyps, colorectal polyps, and gastric polyps, also exploring the mediating role of the gut microbiota. Significant causal associations were identified between specific dietary factors and polyp development, including gut microbiota as a potential mediating pathway, though full peer-review findings were forthcoming at the time of this writing.

Adherence to prudent or fiber-rich dietary patterns, such as the DASH or alternative Mediterranean diet, was associated with a 30–45% reduction in adenoma risk.

5. Dietary and Lifestyle Factors: Summary of Authoritative Evidence

5.1 Foods and Dietary Patterns

• Red and processed meat: Diets high in fat, alcohol, red meat, and low in fiber are associated with increased risk of adenomas and CRC. A meta-analysis found a relative risk for CRC of 1.24 for a 120 g/day increase of red meat and 1.36 for a 30 g/day increase of processed meat.
• Dietary fiber: Higher dietary fiber intake plays an effective role in preventing serrated polyps.
• High-fat diet: High-fat diet was significantly associated with increased polyp risk (OR = 1.45, 95% CI: 1.33–1.57) across subtypes.
• Fruit and vegetables: There is less consistent evidence for fruit and vegetable intake (fiber and folate), fish and omega-3 fatty acids, selenium, dairy, calcium, and vitamin D, but there is convincing evidence that maintaining a healthy weight, avoiding or reducing red meat, alcohol, and smoking may significantly protect against developing colorectal cancer.
• Alcohol: Alcohol was significantly associated with increased polyp risk (OR = 1.63, 95% CI: 1.48–1.78) across subtypes in the 2025 meta-analysis.

5.2 Physical Activity

Physical activity is known to have beneficial effects on skeletal muscle mass, immune function, sleep, and mental health. It also reduces obesity (fat mass), which has a beneficial effect on CRC through a reduction in insulin resistance and inflammation. More recently, physical activity has been linked to improved gut microbiome diversity.

5.3 Gut Microbiome and Lifestyle Interaction

Diet and physical activity were more closely tied to the abundance of CRC-associated gut microbes in people with a history of adenoma than in adenoma-free individuals, suggesting lifestyle may play a particularly important role in shaping these microbes in this high-risk group. Increased physical activity may counteract obesity-induced dysbiosis of the gut microbiome.

5.4 Smoking

Odds ratios for colorectal neoplasms and hyperplastic polyps for heavy smoking of over 20 pack-years were 1.66 (95% CI: 1.05–2.64) and 1.67 (95% CI: 1.01–2.77), respectively. The 2025 meta-analysis identifies smoking as one of the three most impactful modifiable risk factors, with a particularly strong association with sessile serrated lesions.

5.5 Metabolic Conditions

As noted above, type 2 diabetes had the strongest metabolic association with colorectal polyps (OR = 2.17, 95% CI: 1.82–2.60), followed by hyperlipidemia and hypertension. The mechanisms involve chronic hyperinsulinemia, insulin-like growth factor signaling, and chronic low-grade inflammation.

6. Evidence Limitations and Research Gaps

The body of evidence on nutrition and polyps is subject to several inherent limitations that should be acknowledged:

• Most human studies focus on colorectal polyps, especially adenomas. Evidence for dietary influences on nasal, gastric, and gynecological polyps specifically is much more limited and largely derived from Mendelian randomization and observational data.
• Polyp subtype heterogeneity: Associations observed for adenomatous polyps do not necessarily apply to serrated or hyperplastic subtypes. The 2025 Lei meta-analysis specifically highlights subtype-specific effects.
• Bioavailability challenges: The majority of preclinical and clinical studies have found poor oral bioavailability of curcumin, and similar constraints apply to resveratrol, quercetin, and EGCG.
• Study design limitations: Many associations are derived from observational studies susceptible to confounding. RCTs testing dietary interventions often show less clear results than cohort data.
• Combination effects: Despite promising results from experimental studies, only a limited number of phytochemicals have been tested in clinical trials and have shown variable results.

References

• PMC/NIH: Colorectal Polyps (PMC1069054)
• Lei Y et al. (2025). Modifiable lifestyle and metabolic risk factors for colorectal polyps: a systematic review and meta-analysis. Frontiers in Public Health.
• PMC: Lifestyle Factors and Their Combined Impact on the Risk of Colorectal Polyps (PMC3571253)
• Hartman TJ et al. (2005). The association of calcium and vitamin D with risk of colorectal adenomas. J Nutr. PubMed 15671222
• Baron JA et al. (2015). A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. N Engl J Med.
• Grau MV et al. (2003). Vitamin D, calcium supplementation, and colorectal adenomas: randomized trial. PubMed 14652238
• Soutullo-Castiñeiras et al. (2023). The role of vitamin D and calcium in preventing recurrence of colon adenomas. Translational Cancer Research. PMC10583001
• Crockett SD et al. (2019). Calcium and vitamin D supplementation and increased risk of serrated polyps: randomised clinical trial. Gut. PubMed 29496722
• Zhu Z et al. (2023). Association between dietary factors and colorectal serrated polyps: systematic review and meta-analysis. Front Nutr. PMC10413578
• PMC: Association between red and processed meat intake and colorectal adenoma incidence and recurrence: systematic review and meta-analysis (PMC6122348)
• PMC: Diet and supplements and their impact on colorectal cancer (PMC3819783)
• PMC: Role of curcumin in preventing familial adenomatous polyposis (PMC6205744)
• Cruz-Correa M et al. (2006). Combination Treatment With Curcumin and Quercetin of Adenomas in FAP. Clin Gastroenterol Hepatol.
• PMC: Curcumin and Colorectal Cancer: Update and Current Perspective (PMC7438305)
• PMC: A Presurgical Study of Curcumin Combined with Anthocyanin Supplements in Patients with Colorectal Adenomatous Polyps (PMC8539981)
• PMC: Polyphenols in the Prevention and Treatment of Colorectal Cancer: Systematic Review of Clinical Evidence (PMC11357634)
• Oncotarget: Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence
• PMC: Omega-3 Polyunsaturated Fatty Acids, Gut Microbiota, Microbial Metabolites, and Risk of Colorectal Adenomas (PMC9496906)
• PubMed: Omega-3 polyunsaturated fatty acids: moving towards precision use for prevention and treatment of colorectal cancer. PubMed 35115314
• JAMA Oncology: Effect of Marine ω-3 Fatty Acid Supplementation on Risk of Colorectal Adenomas (VITAL ancillary study)
• PMC: seAFOod Polyp Prevention Trial protocol (PMC3733694)
• PMC: Physical activity and risk of colon adenoma: a meta-analysis (PMC3048199)
• PMC: Gut Microbiome and Colorectal Adenomas (PMC4589167)
• Harvard T.H. Chan School of Public Health: Colorectal cancer risk linked to gut microbiome alterations
• PMC: Heredity, symptoms and risk factors of nasal polyps (PMC4493613)
• PMC: Dissecting the causal links between gut microbiome, immune traits and polyp using genetic evidence (PMC11427361)
• PMC: Genetic evidence of dietary patterns and diet-derived antioxidants on polyp development through gut microbiota modulation (PMC12582728)
• PMC: Association of tea and its extracts with colorectal adenomas: meta-analysis and systematic review (PMC10585173)
• PMC: Therapeutic Applications of Nanoformulated Resveratrol and Quercetin in Colorectal Cancer — Updated Review (PMC11206904)
• AME: Prevention of colorectal cancer and dietary management (review)
• PMC: The Gut Microbiome in Early-Onset Colorectal Cancer (PMC12653195)